Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Curevac N.V.
(NQ:
CVAC
)
3.240
-0.010 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Curevac N.V.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
54 Biggest Movers From Friday
October 04, 2021
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc....
Via
Benzinga
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
October 01, 2021
Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector.
Via
InvestorPlace
Exposures
COVID-19
Why Moderna, Novavax And Other COVID-19 Vaccine Stocks Are Plummeting
October 01, 2021
The COVID-19 pandemic proved to be a boon for many biopharma companies that benefited from their foray into the development of vaccines and/or treatments against the novel...
Via
Benzinga
Exposures
COVID-19
Unusual Options Activity Insight: CureVac
August 11, 2021
CureVac (NASDAQ:CVAC) shares experienced unusual options ...
Via
Benzinga
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
September 17, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Breaking Down The Inflation Numbers Draws Attention To Oil Prices
September 15, 2021
Oil futures (/CL) are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However,...
Via
Benzinga
Exposures
Fossil Fuels
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
September 14, 2021
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners.
Via
Talk Markets
Exposures
COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
September 14, 2021
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would...
Via
Benzinga
Exposures
COVID-19
Why CureVac's Stock Is Down During Today's Session
September 14, 2021
CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European...
Via
Benzinga
CureVac Streamlines European Network for mRNA Product Manufacturing
September 14, 2021
- CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands - Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
August 31, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
August 31, 2021
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The...
Via
Benzinga
Exposures
COVID-19
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
August 30, 2021
- Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis - Further research aimed at optimizing mRNA...
From
CureVac
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Death
Intellectual Property
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?
August 27, 2021
It isn't likely.
Via
The Motley Fool
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
August 19, 2021
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.
Via
The Motley Fool
Exposures
COVID-19
4 High-Yield Dividend Stocks to Boost Your Dividend Income
August 17, 2021
Dividends paid by GlaxoSmithKline plc, Vector Group Ltd, Star Group, L.P., and Ennis, Inc translate to high yields at their current price levels.
Via
Talk Markets
Boehringer Ingelheim Scraps Lung Cancer Program With CureVac
August 16, 2021
CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated...
Via
Benzinga
Exposures
COVID-19
Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today
August 16, 2021
Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
August 16, 2021
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update - Continuation of corporate transformation into commercial-ready biopharma company-...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
August 16, 2021
- Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
26 Stocks Moving in Thursday's Pre-Market Session
August 05, 2021
Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed...
Via
Benzinga
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine
July 20, 2021
EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (...
Via
Benzinga
Exposures
COVID-19
Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
July 10, 2021
CureVac aims to become one of Europe's big suppliers.
Via
The Motley Fool
Unusual Options Activity Insight: CureVac
July 07, 2021
On Wednesday, shares of CureVac (NASDAQ:CVAC) saw unusual options activity. After the option alert, the stock price moved down to $59.8. Sentiment: BEARISH Option Type: SWEEP...
Via
Benzinga
South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters
July 06, 2021
South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the...
Via
Benzinga
Exposures
COVID-19
Here's Why You Should Avoid CureVac Stock Like the Plague
July 04, 2021
Funds will not be safe if invested in this coronavirus stock.
Via
The Motley Fool
Exposures
COVID-19
Is CureVac a Bargain Bet on mRNA Vaccine Technology?
July 04, 2021
CureVac shares have slipped more than 20% on bad news.
Via
The Motley Fool
Topics
Cannabis
Exposures
COVID-19
Cannabis
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,...
Via
Talk Markets
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few...
Via
Benzinga
Exposures
Product Safety
Moderna and Pfizer May Benefit From This Rival's Bad News
July 03, 2021
And it could equal billions of dollars for these vaccine leaders.
Via
The Motley Fool
Topics
Cannabis
Exposures
COVID-19
Cannabis
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.